MK-677 Dosage, Reconstitution & Mixing Trends

Explore mk-677 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized mk-677 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What MK-677 Is

MK-677 (ibutamoren) is an orally-active growth-hormone secretagogue most often sourced for GH/IGF-1 and body-composition research. It mimics the peptide ghrelin but is itself a small molecule, not a peptide, with a roughly 24-hour effect on GH and IGF-1. It is usually supplied as capsules or an oral liquid; the FDA has warned against marketing it as a dietary supplement.[1][3]

MK-677 binds and activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus, increasing pulsatile growth hormone (GH) release through both direct pituitary somatotroph stimulation and indirect amplification of endogenous GHRH signalling, with a downstream increase in IGF-1.[2] Ghrelin-receptor activation in the hypothalamus also drives appetite, which is the most-reported subjective effect at consumer doses. Glucose-tolerance worsening and modest insulin resistance are predictable secondary effects of sustained GH/IGF-1 elevation and have been documented in the long-term healthy-elderly trial.[4]

Nass et al. (Ann Intern Med 2008) ran a 2-year randomised placebo-controlled trial of MK-677 25mg/day in healthy elderly adults; the active arm sustained GH and IGF-1 in the young-adult range, increased fat-free mass by ~1.1kg, but did not improve strength or function and worsened fasting glucose and HbA1c.[4] Murphy et al. (J Clin Endocrinol Metab 1998) characterised the GH pharmacodynamics of MK-677.[5] Lumos Pharma is advancing oral MK-677 (LUM-201) in pediatric growth hormone deficiency (OraGrowtH210 and OraGrowtH212 trials), fragile X syndrome, and SHOX deficiency.[1][6]

Not FDA-approved. Lumos Pharma (LUM-201) in active Phase 2/3 development for pediatric GHD, fragile X syndrome, and SHOX deficiency. FDA warning letters against consumer marketing. Not banned by WADA in-competition but classified as a growth-hormone-releasing factor for anti-doping purposes — banned for athletes.

MK-677 Research Sources

MK-677 Dosing Context

MK-677 has a reported half-life of ~24 hours. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. An approximately 24-hour half-life means a single daily dose maintains elevated GH/IGF-1 signalling, with steady state reached over several days. Pharmacokinetic source: Chapman et al. and Merck ibutamoren (MK-677) human PK. It is catalogued under Muscle Peptides on WPA.

MK-677 Community Calculator Data

12 MK-677 reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

MK-677 Research Background and Calculator Data

MK-677 — also known as ibutamoren or by its developer code MK-0677 — is the only molecule in this entire family that is non-peptide and orally bioavailable, and that single fact defines its position in the GH-secretagogue toolkit. The compound was discovered at Merck in the 1990s by the team led by Roy Smith as a small-molecule ghrelin-receptor (GHS-R1a) agonist — a deliberate effort to find a non-peptide that could activate the same growth-hormone-secretagogue receptor pathway as the injectable GHRPs (GHRP-2, GHRP-6, ipamorelin) without requiring subcutaneous administration. The pivotal characterization paper is Patchett et al., Proceedings of the National Academy of Sciences 1995 ("Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue"), which described the molecule's spiropiperidine backbone, its high oral bioavailability, and its ~24-hour duration of GH-secretagogue activity in healthy adults at single oral doses in the 10-25mg range — the pharmacokinetic profile that supports the once-daily oral dosing schedule MK-677 is uniformly used at today.

The most clinically substantive evidence base for MK-677 is the Nass et al., Annals of Internal Medicine 2008 trial — "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults" — which randomized 65 healthy adults aged 60-81 to MK-677 25mg orally once daily or placebo for two years, and reported sustained increases in GH and IGF-1 to levels typical of healthy young adults, alongside meaningful gains in fat-free mass and small drops in LDL cholesterol. The trade-offs reported in that and adjacent ibutamoren studies are real and worth naming: elevated fasting glucose, modest insulin resistance, increased appetite, fluid retention, and a small but measurable rise in cortisol — the side-effect profile that ultimately kept MK-677 from advancing as a Merck pharmaceutical product despite its compelling endocrine signal. The molecule was never approved for any indication, the Merck program was discontinued, and ibutamoren remains a non-FDA-approved research compound available primarily through research-chemical suppliers as an oral capsule or oral solution.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.